Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients

Karci A. C. , CANTÜRK Z., Tarkun I., Cetinarslan B.

ENDOCRINE, vol.57, no.1, pp.148-155, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 57 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1007/s12020-017-1283-8
  • Journal Name: ENDOCRINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.148-155
  • Keywords: Acromegaly, Cathepsin B, Matrix metalloproteinase-2, Matrix metalloproteinase-9, HUMAN PITUITARY-ADENOMAS, IGF-I, DIAGNOSTIC-VALUE, GROWTH-HORMONE, CATHEPSIN-B, GH, METAANALYSIS, DISCREPANT, EXPRESSION, PROTEASES
  • Kocaeli University Affiliated: Yes


During follow-up of acromegaly patients, there is a discordance rate of 30% between the measurements of growth hormone and insulin-like growth factor-1 levels. Further tests are required to determine disease activity in patients with discordant results. This study was planned to investigate an association of serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B with disease activity in acromegaly patients.